^
    5d
    Photodynamic Priming and Minocycline Overcome Chemoresistance by Reprogramming the Pancreatic Tumor Immune Microenvironment In Vivo. (PubMed, Adv Sci (Weinh))
    Here, we use photoactivatable multi-inhibitor liposomes (PMILs) as a clinically translatable strategy to immunomodulate and enhance PDAC treatment using FDA-approved agents: minocycline for tumor priming by downregulating Tdp1, benzoporphyrin derivative incorporated into the liposomal bilayer for photodynamic priming (PDP) of the microenvironment, and irinotecan (IRI) for cytotoxicity. This combination achieved sustained local tumor regression, abscopal effects in untreated distant tumors, and a significant improvement in long-term survival (63%). By integrating clinically approved agents with non-overlapping mechanisms within a light-activated delivery platform, this approach enhances IRI efficacy, reprograms the TME, and promotes antitumor immunity, offering a translatable strategy to sensitize PDAC to chemo- and immunotherapy.
    Preclinical • Journal
    |
    CD8 (cluster of differentiation 8) • ABCG2 (ATP Binding Cassette Subfamily G Member 2)
    |
    irinotecan • minocycline
    8d
    EMPHASIS-2: Efficacy and Safety of Minocycline in Patients With Acute Ischaemic Stroke Receiving Intravenous Thrombolysis (clinicaltrials.gov)
    P3, N=934, Not yet recruiting, Beijing Tiantan Hospital
    New P3 trial
    |
    minocycline
    17d
    Intra-Arterial Neuroprotective Agents and Cold Saline in Ischemic Stroke Intervention (clinicaltrials.gov)
    P1, N=0, Withdrawn, Northwell Health | N=24 --> 0 | Trial completion date: Sep 2025 --> Mar 2026 | Recruiting --> Withdrawn
    Enrollment change • Trial completion date • Trial withdrawal
    |
    minocycline
    28d
    Optimization of Minocycline for Helicobacter Pylori Rescue Treatment (clinicaltrials.gov)
    P4, N=480, Completed, Shanghai Jiao Tong University School of Medicine | Recruiting --> Completed | Trial completion date: Aug 2026 --> Feb 2026 | Trial primary completion date: Aug 2026 --> Feb 2026
    Trial completion • Trial completion date • Trial primary completion date
    |
    minocycline
    1m
    Topical Minocycline for CARP (clinicaltrials.gov)
    P1, N=35, Not yet recruiting, Medical University of South Carolina
    New P1 trial
    |
    minocycline
    2ms
    Memocycline: Reconsolidation Blockade of Intrusive Trauma- and Cocaine-related Memories (clinicaltrials.gov)
    P=N/A, N=138, Completed, Psychiatric University Hospital, Zurich | Active, not recruiting --> Completed | N=210 --> 138 | Trial primary completion date: Nov 2025 --> Mar 2026
    Trial completion • Enrollment change • Trial primary completion date
    |
    minocycline
    2ms
    A Phase 1/2 Study to Evaluate the Safety, PK and Efficacy of TNP-2092 Administered Via IA Injection in PJI Participants (clinicaltrials.gov)
    P1/2, N=33, Recruiting, TenNor Therapeutics Inc. | Trial completion date: Jan 2026 --> Aug 2026 | Trial primary completion date: Jan 2026 --> Aug 2026 | Completed --> Recruiting
    Enrollment open • Trial completion date • Trial primary completion date
    |
    minocycline
    2ms
    A Phase 1/2 Study to Evaluate the Safety, PK and Efficacy of TNP-2092 Administered Via IA Injection in PJI Participants (clinicaltrials.gov)
    P1/2, N=9, Completed, TenNor Therapeutics Inc. | Recruiting --> Completed | N=33 --> 9 | Trial completion date: Aug 2026 --> Jan 2026 | Trial primary completion date: Aug 2026 --> Jan 2026
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    |
    minocycline
    2ms
    Effect of Arestin-Enhanced SRP on Periodontal and Glycemic Outcomes in Diabetics (clinicaltrials.gov)
    P1, N=42, Recruiting, Case Western Reserve University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    minocycline
    2ms
    Fecal Molecular Susceptibility-guided Hp First-line Therapy (clinicaltrials.gov)
    P4, N=544, Not yet recruiting, Shanghai Zhongshan Hospital
    New P4 trial • HEOR
    |
    minocycline
    2ms
    Fecal Molecular Susceptibility-guided Hp Rescue Therapy (clinicaltrials.gov)
    P4, N=290, Not yet recruiting, Shanghai Zhongshan Hospital
    New P4 trial • HEOR
    |
    minocycline
    2ms
    Microglia alter autonomic nuclei neuronal activation after peripheral cytokine challenge. (PubMed, Am J Physiol Cell Physiol)
    When animals were challenged with TNFα after receiving minocycline, fewer c-Fos-positive cells were induced in the DVC and selectively in the rostral VLM. These findings highlight the spatial selectivity of cells in the brainstem to increased peripheral pro-inflammatory signaling, as well as the impact of resident microglia on autonomic circuitry responses.
    Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha) • FOS (Fos Proto-Oncogene AP-1 Transcription Factor Subunit 2)
    |
    minocycline